Buy Ionis Pharmaceuticals (IONS) on Growth Concerns Weakness - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on Weakness
July 25, 2017 1:51 PM EDTBMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $67.00 (from $62.00) while maintaining a Outperform rating.
Analyst Do Kim recommends buying on weakness following Biogen comments on Spinraza growth to slow in 2H17.
"We believe Spinraza has... More
Ionis (IONS) Partner Biogen Reports Blow-Out Spinraza Sales - BMO Capital
July 25, 2017 7:50 AM EDTBMO Capital analyst Do Kim notes Ionis Pharmaceuticals (NASDAQ: IONS) partner Biogen reported 2Q17 Spinraza sales of $203mn, easily beating our $71mn and Street's $75mn.
"Even with rising expectations heading into BIIB's earnings, Spinraza exceeded growing buyside estimates of $100-150mn.... More
